SK279949B6 - Použitie inhibítora komplementu a imunosupresora s - Google Patents

Použitie inhibítora komplementu a imunosupresora s Download PDF

Info

Publication number
SK279949B6
SK279949B6 SK988-91A SK98891A SK279949B6 SK 279949 B6 SK279949 B6 SK 279949B6 SK 98891 A SK98891 A SK 98891A SK 279949 B6 SK279949 B6 SK 279949B6
Authority
SK
Slovakia
Prior art keywords
cyclosporin
complement inhibitor
activity
rejection
immunosuppressor
Prior art date
Application number
SK988-91A
Other languages
English (en)
Slovak (sk)
Inventor
David J. G. White
Den Bogaerde Johan B. Van
Original Assignee
Imutran Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imutran Limited filed Critical Imutran Limited
Publication of SK279949B6 publication Critical patent/SK279949B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
SK988-91A 1990-04-09 1991-04-09 Použitie inhibítora komplementu a imunosupresora s SK279949B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909007971A GB9007971D0 (en) 1990-04-09 1990-04-09 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
SK279949B6 true SK279949B6 (sk) 1999-06-11

Family

ID=10674123

Family Applications (1)

Application Number Title Priority Date Filing Date
SK988-91A SK279949B6 (sk) 1990-04-09 1991-04-09 Použitie inhibítora komplementu a imunosupresora s

Country Status (22)

Country Link
EP (1) EP0527762B1 (enExample)
JP (1) JP3518547B2 (enExample)
CN (1) CN1040178C (enExample)
AT (1) ATE141167T1 (enExample)
AU (1) AU7555591A (enExample)
CZ (1) CZ283119B6 (enExample)
DE (1) DE69121401T2 (enExample)
DK (1) DK0527762T3 (enExample)
ES (1) ES2090325T3 (enExample)
GB (1) GB9007971D0 (enExample)
GR (1) GR3021642T3 (enExample)
HK (1) HK48597A (enExample)
IE (1) IE911153A1 (enExample)
IL (1) IL97788A (enExample)
IN (1) IN173149B (enExample)
MY (1) MY106158A (enExample)
NZ (1) NZ237739A (enExample)
PT (1) PT97277B (enExample)
SG (1) SG47465A1 (enExample)
SK (1) SK279949B6 (enExample)
WO (1) WO1991015221A1 (enExample)
ZA (1) ZA912467B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE297217T1 (de) 1999-10-27 2005-06-15 Alexandra Lucas Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
US7419670B2 (en) 2000-09-29 2008-09-02 Viron Therapeutics, Inc. Method of treating arthritis with SERP-1 and an immunosuppressant
EP2338511A3 (en) * 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
JP6223659B2 (ja) 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
WO2026064591A1 (en) * 2024-09-20 2026-03-26 Antinous Technology Company Limited Methods and compositions for preventing herpes virus reactivation in organ xenograft

Also Published As

Publication number Publication date
HK48597A (en) 1997-04-25
IL97788A (en) 1998-02-08
JPH05507266A (ja) 1993-10-21
IE911153A1 (en) 1991-10-09
DK0527762T3 (da) 1996-09-02
CN1056240A (zh) 1991-11-20
GR3021642T3 (en) 1997-02-28
SG47465A1 (en) 1998-04-17
IN173149B (enExample) 1994-02-19
GB9007971D0 (en) 1990-06-06
EP0527762A1 (en) 1993-02-24
PT97277B (pt) 1998-08-31
AU7555591A (en) 1991-10-30
MY106158A (en) 1995-03-31
ZA912467B (en) 1992-12-30
CN1040178C (zh) 1998-10-14
EP0527762B1 (en) 1996-08-14
IL97788A0 (en) 1992-06-21
WO1991015221A1 (en) 1991-10-17
ATE141167T1 (de) 1996-08-15
JP3518547B2 (ja) 2004-04-12
CZ283119B6 (cs) 1998-01-14
NZ237739A (en) 1993-09-27
DE69121401T2 (de) 1996-12-12
ES2090325T3 (es) 1996-10-16
CS9100988A2 (en) 1991-12-17
PT97277A (pt) 1992-01-31
DE69121401D1 (de) 1996-09-19

Similar Documents

Publication Publication Date Title
CRAMER et al. Cardiac transplantation in the rat: II. Alteration of the severity of donor graft arteriosclerosis by modulation of the host immune response
RU2014837C1 (ru) Средство для лечения панкреатита и предупреждения отторжения трансплантата поджелудочной железы и способ предупреждения отторжения трансплантата поджелудочной железы
SQUIFFLET et al. Combined immunosuppressive therapy with cyclosporin A and azathioprine: a synergistic effect in three of four experimental models
Hiestand et al. Comparison of the pharmacological profiles of cyclosporine,(Nva2)-cyclosporine and (Val2) dihydro-cyclosporine
Myburgh et al. Total lymphoid irradiation in renal transplantation
US8435520B2 (en) Combinations of immunosuppressive agents for the treatment or prevention of graft rejections
JP3518547B2 (ja) 同種移植および調和異種移植の拒否反応の阻害
Colebrook et al. Effect of cyclosporin A on the survival and ultrastructure of Echinococcus granulosus protoscoleces in vitro
US20010018051A1 (en) Inhibition of allograft and concordant xenograft rejection
Anderson et al. Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation
EP1240904B1 (de) Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstossung von Xenotransplantaten in Säugetieren
AU618838B2 (en) Use of castanospermine as an anti-inflammatory and immunosuppressant agent
JPH09506115A (ja) 細胞毒性薬の副作用を軽減するためのトランスフェリン組成物
US5736136A (en) Immunoglobulin infusion in xenotransplantation
Hwang et al. Ketoconazole and High-Dose Methylprednisolone Predisposing to Cyclosporine-lnduced Seizures: Report of 3 Cases
Kobayashi et al. Prolongation of xenograft survival by cobra venom factor
US6503948B2 (en) Method for prevention or treatment of acute allograft rejection and a pharmaceutical composition therefor
Cofer et al. Effects of pre-and postengraftment donor-specific transfusions and cyclosporine on the enhancement of experimental allograft survival
Kahn et al. Use of verapamil with conventional immunosuppression after porcine renal transplantation
JPH06505628A (ja) ｉｎ　ｖｉｖｏで増殖する不死化細胞によるタンパク質の生産
de Bruin et al. The effect of pretransplant donor-specific blood transfusions on various segments of small bowel grafts
Pruitt et al. Soluble Complement Receptor and Hyperacute Rejection
Murase et al. Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation
Tufveson et al. Tolerance or Rejection: A Delicate Balance as Judged by Exposure of Heart‐Transplanted Rats to the Immunomodulator Linomide®
Sanfillippo Randall Bollinger, MD, Ph. D., Henry C. March, Jr., Ph. D., and Fred